BioPharmSignal logoBioPharmSignal

Biotech News

Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology

Pulse Biosciences (PLSE)Pulse BiosciencesCompany update

HAYWARD, Calif. --(BUSINESS WIRE)--Mar. 12, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first patient enrollments in the multi-center

Open original release

Related news

PLSEPulse Biosciences2026-04-20 11:00 EST

Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

PLSEPulse Biosciences2026-03-09 11:00 EST

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

ICCMIceCure Medical2026-07-27 12:32 EST

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

TCMDTactile Systems Technology, Inc.2026-05-04 20:05 EST

Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results

HYPRHyperfine2026-04-29 12:15 EST

Hyperfine Swoop® System Introduced as India’s First Portable MRI for Bedside Brain Imaging at the Country’s Leading Medical Institution

IRIXIRIDEX2026-04-07 20:05 EST

Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology

STIMNeuronetics2026-05-14 12:32 EST

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

DCTHDelcath Systems2026-04-06 12:30 EST

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

ANGOAngioDynamics2026-05-27 12:30 EST

AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

IRIXIRIDEX2026-05-19 20:05 EST

Iridex Reports First Quarter 2026 Financial Results

View all latest news

Pulse Biosciences

Pulse Biosciences is a medical technology company focused on nano-pulse stimulation and nonthermal cellular treatments. Its platform is intended to create new ways to treat tissue while preserving surrounding structures.

Recent company news

PLSEPulse Biosciences2026-05-27 20:05 EST

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

PLSEPulse Biosciences2026-05-12 11:00 EST

ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

PLSEPulse Biosciences2026-05-08 11:00 EST

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

PLSEPulse Biosciences2026-05-04 11:00 EST

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

PLSEPulse Biosciences2026-04-25 17:00 EST

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Stock data

Close
32.79 USD
Market cap
1.68B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States